Corline Biomedical (CLBIO) Q3 2025 earnings summary

Executive summary

• Achieved a breakthrough period with FDA approval for a partner's product using CHSTM technology and a 10-year license and supply agreement with Kardium.

• Raised 23 MSEK through a directed share issue to Eiffel Investment Group to support expansion, especially in the US.

• Focused on scaling production and ensuring quality to meet anticipated demand from Kardium and future customers.

Financial highlights

• Net sales for Q3 2025 were 1,305 KSEK, down from 1,770 KSEK in Q3 2024; for Jan–Sep 2025, net sales were 5,547 KSEK, down from 7,763 KSEK year-over-year.

• Result after financial items for Q3 2025 was -3,359 KSEK (Q3 2024: -2,996 KSEK); Jan–Sep 2025: -9,687 KSEK (Jan–Sep 2024: -9,033 KSEK).

• Earnings per share for Q3 2025 were -0.14 SEK (unchanged year-over-year); Jan–Sep 2025: -0.40 SEK (-0.42 SEK year-over-year).

• Cash and cash equivalents at September 30, 2025, were 5.8 MSEK (7.3 MSEK year-over-year).

• Equity at period end was 77,227 KSEK (84,506 KSEK year-over-year); equity ratio 94% (91%).

Outlook and guidance

• Anticipates increased revenues and financial stability from the long-term Kardium agreement and new capital injection.

• Plans to expand the customer base in the US and Europe, reducing dependency on a single client.

• Detailed commercial expansion plan for the US to be presented in Q1 2026.